{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-058747","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.198991+00:00","generated_at":"2026-06-02T08:36:50.164479+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Innoviva Q1 net income $36.5M ($0.58 basic EPS); product sales up 66% YoY to $19.1M; GSK royalties $61.9M","bullets":["Net income $36.5M ($0.58 basic EPS) vs $34.9M ($0.51) in Q1 2023.","Net product sales $19.1M, +66% YoY, driven by XACDURO launch and GIAPREZA growth.","GSK royalty revenue $61.9M, up from $60.3M in Q1 2023.","Repurchased 0.6M shares for $9.7M in Q1 2024; completed $5.3M buyback post-quarter.","Positive Phase 3 zoliflodacin results for uncomplicated gonorrhea; NDA submission expected early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-058747","json":"https://secwatch.observer/filing/0001104659-24-058747.json","markdown":"https://secwatch.observer/filing/0001104659-24-058747.md","text":"https://secwatch.observer/filing/0001104659-24-058747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924058747/0001104659-24-058747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924058747/tm2413603d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:36:50.164479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a2d04d5f568744547e1e1623f075183b0de8e58","claim":"Innoviva, Inc. reported first quarter ended March 31, 2024 results: net income $36.5 million, or $0.58 basic per share.","evidence_excerpt":"Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924058747/0001104659-24-058747-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$36.5 million, or $0.58 basic per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}